Meta Pharmaceuticals, a corporation engaged in the manufacturing, research, and development of pharmaceuticals and medical devices, reported sales of 32.5 billion won and an operating profit of 7.14 billion won for the previous year on the 11th. Compared to 2023, sales and operating profit increased by 58% and 152%, respectively.
Meta Pharmaceuticals has recorded the highest annual sales for five consecutive years since its establishment. It has also maintained profitable management for four years. A representative from Meta Pharmaceuticals noted, “The lifting procedure’s Polydioxanone absorbable suture (lifting thread) 'Minithing' has driven sales,” and added, “Dental implants 'Plan Implant' and hair transplant devices have also contributed to the growth.” They further stated, “The major medical device and pharmaceutical supply business is also growing, expanding sales.”
Minithing, Meta Pharmaceuticals' core product, features a unique hook design and over 20% greater tensile strength compared to competing products, improving the procedural usability for medical professionals, providing strong traction, and ensuring long-lasting lifting effects. Meta Pharmaceuticals plans to introduce Minithing in more than 20 countries, including North America, Europe, and Southeast Asia.
Meta Pharmaceuticals has also decided to focus on the export of its self-manufactured dental implants. It has obtained certification from the U.S. Food and Drug Administration (FDA) and the European Conformity (CE). Meta Pharmaceuticals assessed that it has secured market competitiveness by applying the materials, technology, and design used in high-priced implants while maintaining reasonable prices.
Lee Su-jin, the CEO of Meta Pharmaceuticals, stated, “This year, we will expand the global supply chain of our self-developed medical devices and achieve significant business growth through investments in and mergers and acquisitions (M&A) of promising medical device manufacturing companies.”